BIO logo

  • June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading
Search Filters
  • Date
  • Focus Area
  • Start time
  • Session Type
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
1:00 PM – 5:00 PM
(PST)
  1. Registration
    Session
  2. Registration - Marriott Marquis Satellite Location
    Session
7:00 AM – 5:30 PM
(PST)
  1. Registration
    Session
  2. Registration - Marriott Marquis Satellite Location
    Session
1:00 AM – 2:00 AM
(PST)
  1. AaviGen
    CP
    • Cell and Gene Therapy and Genome Editing
  2. AAVogen
    CP
    • Cell and Gene Therapy and Genome Editing
  3. Accelerated Biosciences Corp.
    CP
    • Cell and Gene Therapy and Genome Editing
  4. Accession Therapeutics Limited
    CP
    • Oncology
  5. Accuredit Therapeutics US limited
    CP
    • Cell and Gene Therapy and Genome Editing
  6. Accuronix Therapeutics, Inc.
    CP
    • Oncology
  7. ADP
    CP
    • Other
  8. ADvantage Therapeutics Inc.
    CP
    • CNS/Neurological
  9. AIVITA Biomedical, Inc.
    CP
    • Oncology
  10. Alphyn Biologics, Inc.
    CP
    • Dermatology
  11. Amgen Inc.
    CP
    • Multiple Therapeutics
  12. Apollomics
    CP
    • Oncology
  13. ARC Medical Inc.
    CP
    • Medical Devices
  14. Artax Biopharma
    CP
    • Immunology
  15. Aruna Bio
    CP
    • CNS/Neurological
  16. Asahi Kasei Pharma corporation
    CP
    • Immunology
  17. Aurion Biotech
    CP
    • Cell and Gene Therapy and Genome Editing
  18. AustarPharma,LLC
    CP
    • Metabolic Diseases
  19. Auxergen, Inc.
    CP
    • Food and Agriculture
  20. Avanzanite Bioscience
    CP
    • Orphan and Rare Disease
  21. Avelos Therapeutics
    CP
    • Oncology
  22. Avery Therapeutics, Inc.
    CP
    • Platform for Therapeutics
  23. Avidicure B.V.
    CP
    • Oncology
  24. Avistone Biotechnology
    CP
    • Oncology
  25. Avstera Therapeutics Corp.
    CP
    • Oncology
  26. Azitra Inc.
    CP
    • Dermatology
  27. Azome Therapeutics Inc
    CP
    • Inflammation
  28. Bexion Pharmaceuticals
    CP
    • Oncology
  29. Bilayer Therapeutics, Inc.
    CP
    • Metabolic Diseases
  30. BioMap
    CP
    • Platform for Therapeutics
  31. Bionaut
    CP
    • CNS/Neurological
  32. Bionomics Ltd
    CP
    • CNS/Neurological
  33. Bionoxx Inc.
    CP
    • Oncology
  34. Biopico Systems Inc
    CP
    • Tools/Drug Development Support Tech
  35. Biorchestra
    CP
    • CNS/Neurological
  36. BlueSphere Bio
    CP
    • Cell and Gene Therapy and Genome Editing
  37. Boehringer Ingelheim
    CP
    • Multiple Therapeutics
  38. Boehringer Ingelheim Animal Health
    CP
    • Animal Health Products
  39. Boryung Co., Ltd.
    CP
    • Oncology
  40. BrainStorm Therapeutics, Inc.
    CP
    • CNS/Neurological
  41. Breye Therapeutics
    CP
    • Ophthalmology
  42. Bridge Biotherapeutics
    CP
    • Multiple Therapeutics
  43. Brii Biosciences
    CP
    • Multiple Therapeutics
  44. Bristol Myers Squibb
    CP
    • Multiple Therapeutics
  45. BTB Therapeutics
    CP
    • Pain Management
  46. Cairn Therapeutics
    CP
    • Oncology
  47. Caliway Biopharmaceuticals Co.,Ltd.
    CP
    • Multiple Therapeutics
  48. Calviri
    CP
    • Oncology
  49. CeleCor Therapeutics
    CP
    • Cardiovascular
  50. Cellphire Therapeutics, Inc
    CP
    • Multiple Therapeutics
  51. Cellusion Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  52. Centivax, Inc.
    CP
    • Infectious Disease and Vaccines
  53. Ceria Therapeutics, Inc.
    CP
    • Platform for Therapeutics
  54. Chimeric Therapeutics
    CP
    • Cell and Gene Therapy and Genome Editing
  55. Chugai Pharmaceutical Co., Ltd.
    CP
    • Multiple Therapeutics
  56. Coastar Therapeutics Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  57. Combined Therapeutics
    CP
    • Immunology
  58. Company Presentations
    Company Presentation
  59. Concerto Biosciences
    CP
    • Platform for Therapeutics
  60. CorrectSequence Therapeutics
    CP
    • Cell and Gene Therapy and Genome Editing
  61. Cradle
    CP
    • Tools/Drug Development Support Tech
  62. Cytimm Therapeutics
    CP
    • Oncology
  63. Cytiva
    CP
    • Multiple Therapeutics
  64. Cytotheryx
    CP
    • Platform for Therapeutics
  65. Daré Bioscience
    CP
    • Reproductive/Sexual Health
  66. Data4Cure, Inc.
    CP
    • Tools/Drug Development Support Tech
  67. DermaXon LLC
    CP
    • Dermatology
  68. Diakonos Oncology
    CP
    • Oncology
  69. Doloromics
    CP
    • Pain Management
  70. Dyadic International Inc.
    CP
    • Platform for Therapeutics
  71. Editpep
    CP
    • CNS/Neurological
  72. EG 427
    CP
    • Cell and Gene Therapy and Genome Editing
  73. Enveda Biosciences
    CP
    • Inflammation
  74. EpiAxis Therapeutics
    CP
    • Oncology
  75. Epion Therapeutics
    CP
    • Ophthalmology
  76. Esphera SynBio Inc
    CP
    • Oncology
  77. Evaxion Biotech
    CP
    • Immunology
  78. Evive Biotech
    CP
    • Multiple Therapeutics
  79. Exeliom Biosciences
    CP
    • Inflammation
  80. Extend Biosciences
    CP
    • Metabolic Diseases
  81. Eydisbio Inc.
    CP
    • Orphan and Rare Disease
  82. FibroBiologics Clinical Update
    CP
    • Regenerative Medicine
  83. First Wave BioPharma, Inc.
    CP
    • Gastrointestinal
  84. Forge Biologics
    CP
    • Cell and Gene Therapy and Genome Editing
  85. Freedom Biosciences
    CP
    • CNS/Neurological
  86. Future Medicine
    CP
    • Metabolic Diseases
  87. Gan & Lee Pharmaceuticals
    CP
    • Multiple Therapeutics
  88. GC Cell
    CP
    • Cell and Gene Therapy and Genome Editing
  89. GelMEDIX, Inc.
    CP
    • Ophthalmology
  90. GenEdit
    CP
    • Multiple Therapeutics
  91. GenEndeavor LLC
    CP
    • Diagnostics and Personalized Medicine
  92. Genentech, a Member of the Roche Group
    CP
    • Multiple Therapeutics
  93. GeneVentiv Therapeutics, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  94. Genprex, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  95. GenVivo, Inc.
    CP
    • Oncology
  96. GeoVax Labs, Inc.
    CP
    • Immunology
  97. GlueTacs Therapeutics
    CP
    • Oncology
  98. Glykos Finland Oy
    CP
    • Oncology
  99. Greenwich LifeSciences
    CP
    • Oncology
  100. GSK
    CP
    • Multiline Global Biopharma
  101. GSNO Therapeutics, Inc.
    CP
    • Immunology
  102. Guangzhou Magpie Pharmaceuticals Co., Ltd.
    CP
    • CNS/Neurological
  103. Hillhurst Bio
    CP
    • Multiple Therapeutics
  104. Hopstem Biotechnology
    CP
    • CNS/Neurological
  105. Humanetics Corporation
    CP
    • Multiple Therapeutics
  106. HysensBio
    CP
    • Regenerative Medicine
  107. Immunartes LLC
    CP
    • Infectious Disease and Vaccines
  108. Immunic Therapeutics
    CP
    • CNS/Neurological
  109. Immunis, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  110. ImmunoForge Co., Ltd.
    CP
    • Orphan and Rare Disease
  111. Immuto Scientific
    CP
    • Platform for Therapeutics
  112. Inhalon Biopharma, Inc.
    CP
    • Respiratory
  113. Inimmune Inc.
    CP
    • Immunology
  114. Inocras Inc.
    CP
    • Diagnostics and Personalized Medicine
  115. inSoma Bio
    CP
    • Regenerative Medicine
  116. InvivoSciences, Inc.
    CP
    • Cardiovascular
  117. IRBM
    CP
    • Multiple Therapeutics
  118. Juncell Therapeutics
    CP
    • Cell and Gene Therapy and Genome Editing
  119. Kannalife Sciences, Inc.
    CP
    • Inflammation
  120. Kayothera
    CP
    • Platform for Therapeutics
  121. Kinoxis Therapeutics
    CP
    • CNS/Neurological
  122. Know Labs, Inc.
    CP
    • Medical Devices
  123. Küleon Biosciences
    CP
    • CNS/Neurological
  124. L&J Bio,Co.,Ltd.
    CP
    • CNS/Neurological
  125. Lectenz Bio
    CP
    • Tools/Drug Development Support Tech
  126. Likarda, Inc
    CP
    • Platform for Therapeutics
  127. Lineage Cell Therapeutics
    CP
    • Regenerative Medicine
  128. Lisata Therapeutics
    CP
    • Oncology
  129. Lumos Pharma
    CP
    • Orphan and Rare Disease
  130. Lynk Pharmaceuticals
    CP
    • Multiple Therapeutics
  131. Lynthera Corporation
    CP
    • Ophthalmology
  132. Lyvgen Biopharma
    CP
    • Oncology
  133. Macrobiome Therapeutics
    CP
    • Immunology
  134. MAIA Biotechnology, Inc.
    CP
    • Oncology
  135. Medicus Pharma LTD.
    CP
    • Dermatology
  136. Mediwhale Inc.
    CP
    • AI and Digital Health
  137. Medosome Biotec, LLC
    CP
    • Multiple Therapeutics
  138. Mekonos
    CP
    • Cell and Gene Therapy and Genome Editing
  139. Merck
    CP
    • Multiple Therapeutics
  140. Miracure Biotechnology
    CP
    • Infectious Disease and Vaccines
  141. miRecule Inc.
    CP
    • Platform for Therapeutics
  142. Moonwalk Biosciences, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  143. Neuracle Genetics
    CP
    • Ophthalmology
  144. Neuren Pharmaceuticals
    CP
    • CNS/Neurological
  145. Neurobiogen
    CP
    • CNS/Neurological
  146. Novoron Bioscience
    CP
    • CNS/Neurological
  147. Nxera Pharma
    CP
    • Multiple Therapeutics
  148. OBI Pharma, Inc.
    CP
    • Oncology
  149. Ocugen, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  150. Olatec Therapeutics
    CP
    • Inflammation
  151. Orca Bio
    CP
    • Oncology
  152. Orizuru Therapeutics, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  153. Osmol Therapeutics, Inc.
    CP
    • Oncology
  154. Oxford Biotherapeutics
    CP
    • Oncology
  155. Panolos Bioscience, Inc.
    CP
    • Multiple Therapeutics
  156. Papillon Therapeutics, Inc.
    CP
    • Cell and Gene Therapy and Genome Editing
  157. PassPort Technologies, Inc.
    CP
    • Platform for Therapeutics
  158. Pattern Computer
    CP
    • Tools/Drug Development Support Tech
  159. PDX Pharmaceuticals
    CP
    • Oncology
  160. Pelagos Pharmaceuticals, Inc.
    CP
    • Cardiovascular
  161. Pending AI
    CP
    • Platform for Therapeutics
  162. Pepper Bio
    CP
    • Oncology
  163. Percheron Therapeutics Limited
    CP
    • Orphan and Rare Disease
  164. Phrontline Biopharma
    CP
    • Oncology
  165. Pirouette Medical Inc.
    CP
    • Medical Devices
  166. PlaqueTec
    CP
    • Cardiovascular
  167. Praetego Inc
    CP
    • CNS/Neurological
  168. Predictive Oncology
    CP
    • Oncology
  169. Profluent Bio
    CP
    • Cell and Gene Therapy and Genome Editing
  170. Protalix Biotherapeutics
    CP
    • Cell and Gene Therapy and Genome Editing
  171. Psilera
    CP
    • CNS/Neurological
  172. QBiotics Group Limited
    CP
    • Oncology
  173. Qprotyn Inc
    CP
    • Platform for Therapeutics
  174. RADIOPHARM THERANOSTICS
    CP
    • Oncology
  175. Rakuten Medical, Inc.
    CP
    • Oncology
  176. Recce Pharmaceuticals
    CP
    • Infectious Disease and Vaccines
  177. ReCode Therapeutics
    CP
    • Other
  178. Rejuvenate Biomed
    CP
    • Platform for Therapeutics
  179. Rejuvenation Technologies
    CP
    • Regenerative Medicine
  180. Reveal Pharma
    CP
    • Oncology
  181. Sanofi
    CP
    • Multiple Therapeutics
  182. Sarcomatrix Therapeutics Corp.
    CP
    • Cell and Gene Therapy and Genome Editing
  183. scPharmaceuticals
    CP
    • Cardiovascular
  184. Serpass Biologics, Inc.
    CP
    • Inflammation
  185. Servier
    CP
    • Oncology
  186. Shanghai Novamab Biopharmaceuticals Co., Ltd.
    CP
    • Immunology
  187. Shanghai Synergy Pharmaceutical Sciences Co., Ltd., A wholly owned subsidiary of Huahai Pharmaceutical Co., Ltd.
    CP
    • Multiple Therapeutics
  188. Silver Creek Pharmaceuticals
    CP
    • CNS/Neurological
  189. Sinopia Biosciences, Inc.
    CP
    • CNS/Neurological
  190. SIRPant Immunotherapeutics Inc
    CP
    • Cell and Gene Therapy and Genome Editing
  191. Sobrera Pharma
    CP
    • CNS/Neurological
  192. SPOC Proteomics
    CP
    • Tools/Drug Development Support Tech
  193. STALICLA SA
    CP
    • CNS/Neurological
  194. StemSynergy Therapeutics
    CP
    • Oncology
  195. Talus Bio
    CP
    • Platform for Therapeutics
  196. TechInvention Lifecare Pvt Ltd
    CP
    • Infectious Disease and Vaccines
  197. Tharimmune, Inc.
    CP
    • Multiple Therapeutics
  198. Theradaptive, Inc.
    CP
    • Regenerative Medicine
  199. Tiba Biotech LLC
    CP
    • Immunology
  200. Tonix Pharmaceuticals Holding Corp.
    CP
    • CNS/Neurological
    Jessica Morris
    Jessica Morris, Chief Operating Officer - TONIX Pharmaceuticals
  201. Transcend Therapeutics
    CP
    • CNS/Neurological
  202. TransCode Therapeutics
    CP
    • Oncology
  203. Triastek, Inc.
    CP
    • Other
  204. Turing Biosciences LLC
    CP
    • Platform for Therapeutics
  205. Umoja Biopharma
    CP
    • Cell and Gene Therapy and Genome Editing
  206. Varda Space Industries, Inc.
    CP
    • Platform for Therapeutics
  207. Vasomune Therapeutics Inc
    CP
    • Respiratory
  208. Vaxxas
    CP
    • Medical Devices
  209. VelaVigo
    CP
    • Oncology
  210. Ventrix
    CP
    • Regenerative Medicine
  211. Virpax Pharmaceuticals, Inc.
    CP
    • Pain Management
  212. Vivacelle Bio,Inc.
    CP
    • Multiple Therapeutics
  213. VRG Therapeutics
    CP
    • Immunology
  214. VSPharmTech
    CP
    • Oncology
  215. XORTX Therapeutics Inc.
    CP
    • Other
  216. XyloCor Therapeutics
    CP
    • Cardiovascular
  217. Zambon Biotech SA
    CP
    • CNS/Neurological
  218. Ziphius
    CP
    • Immunology
  219. Zoetis
    CP
    • Animal Health Products
  220. ZTI BIOSCIENCES
    CP
    • Other
  221. Zymeworks
    CP
    • Other
6:30 AM – 7:00 PM
(PST)
  1. KBI Biopharma 5K at BIO 2024
    Session
  2. Registration
    Session
  3. Registration - Marriott Marquis Satellite Location
    Session
9:00 AM – 12:00 PM
(PST)
  1. Partnering with the U.S. Government to Achieve Our National Security Mission
    Breakout Session
    • Infectious Disease and Vaccines
    28ABCDE
9:05 AM – 9:40 AM
(PST)
  1. Opening Remarks
    DOD/BARDA
    • Infectious Disease and Vaccines
    Paul Friedrichs
    Paul Friedrichs, Director - Office of Pandemic Preparedness and Response Policy (OPPR)
    David Smith
    David Smith, Deputy Assistant Secretary of Defense for Health Readiness Policy and Oversight - Department of Defense (DOD)
9:45 AM – 10:40 AM
(PST)
  1. US and Global Partnerships to Achieve Better Global Preparedness and Response
    DOD/BARDA
    • Infectious Disease and Vaccines
    Jennifer Alton
    Jennifer Alton, President - Pathway Policy Group
    Chris Houchens
    Chris Houchens, Director Division CBRN MCMs - BARDA
    Karin Bok
    Karin Bok, Acting Deputy Director and Director of Pandemic Preparedness and Emergency Response VRC, NIAID - National Institutes of Health (NIH)
    Emma Wheatley
    Emma Wheatley, Director, Access and Private Partnerships - CEPI
    Timothy Belski
    Timothy Belski, Branch Chief, Biopharmaceutical Manufacturing Preparedness (BioMaP) - BARDA
    Laurent Muschel
    Laurent Muschel, Acting Director General - European Commission, Health Emergency Preparedness and Response Authority (HERA)
    Brad Norwood
    Brad Norwood, Division Chief, Advanced and Emerging Threats, Joint Science and Technology Office - Defense Threat Reduction Agency
    Nicole Kilgore
    Nicole Kilgore, JPEO-CBRND - Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense/Joint Pro
10:00 AM – 11:00 AM
(PST)
  1. APAC: A Top Rate Destination for Complex and Challenging Clinical Trials
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    novotech
10:45 AM – 11:30 AM
(PST)
  1. Aiming at a Moving Target: Enabling Technology to Adapt to Evolving Threats
    DOD/BARDA
    • Infectious Disease and Vaccines
    Taylor Sexton
    Taylor Sexton, Principal, Health Policy and Medical Countermeasures - Todd Strategy Group
    Bruce Goodwin
    Bruce Goodwin
    Arlene Joyner
    Arlene Joyner, Deputy Assistant Secretary Director, Office of Industrial Base Management and Supply Chain, ASPR - HHS
    David Kaslow
    David Kaslow, Director, Office of Vaccine Research and Review, CBER - FDA
    Wolfgang Philipp
    Wolfgang Philipp, Principal Advisor – Chief Science Officer - HERA
11:35 AM – 11:55 AM
(PST)
  1. Unlocking the Door to Government Partnerships
    DOD/BARDA
    • Infectious Disease and Vaccines
    Jeremiah Kelly
    Jeremiah Kelly, Partner - Venable LLP
    Gary Disbrow
    Gary Disbrow, Deputy Assistant Secretary Director - BARDA
    Matt Clark
    Matt Clark, Chemical, Biological, Radiological and Nuclear (CBRN) Medical Joint Project Manager - JPEO-CBRND
    Richard Schoske
    Richard Schoske, Chief, Diagnostics and Detection, JSTO - DTRA
12:00 PM – 1:00 PM
(PST)
  1. How to Build a Successful and Competitive Biopharma Ecosystem in Southeast Asia
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Mai Zymaris
    Mai Zymaris, Counsel - Baker McKenzie
    Phong Tran
    Phong Tran, CEO - BOUND Therapeutics and siRnaMed Therapeutics
    John Mattison
    John Mattison, Operating Partner and Chief Medical Information Officer - Arsenal Capital Partners
    Anh Hoang-Lindsay
    Anh Hoang-Lindsay, CEO - Jana Care
    Alex Wang
    Alex Wang, Head of Business Development, US & China - Zuellig Pharma
1:45 PM – 2:45 PM
(PST)
  1. A Discussion on Increasing Healthspan
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hilary Brueck
    Hilary Brueck, Journalist - Business Insider
    Dan Oliver
    Dan Oliver, CEO & Co-Founder - Rejuvenate Bio
    Katharine Grabek
    Katharine Grabek, Co-Founder and CSO - Fauna Bio
    Jake Becraft
    Jake Becraft, CEO & Founder - Strand Therapeutics
    Alex Aravanis
    Alex Aravanis, CEO - Moonwalk Biosciences
    Jennifer Bergheiser
    Jennifer Bergheiser, Chief Business Officer - eGenesis
  2. A Licensing Deal for All Seasons
    Breakout Session
    • Business Development and Finance
    29AB
    Jonathan Grinstein
    Jonathan Grinstein, North American Editor - Inside Precision Medicine
    Uneek Mehra
    Uneek Mehra, CHIEF FINANCIAL & BUSINESS OFFICER - 4DMT
    Kunal Patel
    Kunal Patel, VP of Business Development - Synthekine
    Gavin Samuels
    Gavin Samuels, Chief Business Officer - CinRx Pharma
    Lesley Stolz
    Lesley Stolz, Vice President - Johnson & Johnson Innovation
    Richard Wilson
    Richard Wilson, Senior VP, Primary Focus Lead of Genetic Regulation - Astellas Gene Therapies
  3. All Money is NOT Created Equal: The Differences between Angel, Venture and Strategic Capital in the Biotech Funding Ecosystem
    Breakout Session
    • Business Development and Finance
    32AB
    Yaniv Sneor
    Yaniv Sneor, Founder & Managing Director - Mid Atlantic Bio Angels
    Jonathan McClain
    Jonathan McClain, Executive Director, Eli Lilly Catalyze team - Eli Lilly
    Max Farina
    Max Farina, Senior Associate - 5AM Ventures
  4. Alternative Funding Programs: Protecting Patients in an Ever-Changing Healthcare Landscape
    Breakout Session
    • Patient Advocacy
    26A
    Ashira Vantrees
    Ashira Vantrees, Counsel - Aimed Alliance
    Kollet Koulianos
    Kollet Koulianos, Vice President Payer Relations - National Hemophilia Foundation
    Kim Czubaruk
    Kim Czubaruk, Associate Vice President of Policy - Cancer Care
    Richard Meyers
    Richard Meyers, Head, State Policy - Bristol Myers Squibb
  5. Building Capacities in the Industry for Secondary Uses of Health Data: The EHDS Framework
    Breakout Session
    • AI and Digital Health
    24BC
    Montse Daban
    Montse Daban, Director of Strategic Foresight and International Relations and President - Biocat and The Council of European BioRegions
    Jean Marc Bourez
    Jean Marc Bourez, CEO - EIT Heatlth
    Elina Drakvik
    Elina Drakvik, Senior lead, Health Data 2030 - Sitra
    Christopher Morton
    Christopher Morton, Business Executive and Ceo - ELEM Biotech
    Aenor Sawyer
    Aenor Sawyer, Director UC Space Health - University of San Francisco
    Brad Ship
    Brad Ship, Partner - Alira Health
  6. Empowering Real World Patient-Centric Digital Health in Asia with Digital Apps
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Tsu-Hui Liu
    Tsu-Hui Liu, Director of Biotechnology, Health, Medicine and Agriculture Division, - Office of Science and Technology Policy, National Science and Technology Council (NSTC)
    Jared Josleyn
    Jared Josleyn, Global Head of Digital Healthcare - Sanofi
    Chu-Yie Deng
    Chu-Yie Deng, co-founder and CEO - Health2Sync
    Allen Lien
    Allen Lien, Chairman & CEO - Acer Medical Inc.
  7. Europe's Policy Environment and the Impact on the Biotech Sector
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Justin Pine
    Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)
    Matias Olsen
    Matias Olsen, Public Affairs & Policy Manager - EUCOPE
    Claire Skentelbery
    Claire Skentelbery, Director General - EuropaBio
    Santoke Naal
    Santoke Naal, Managing Director - IGES UK
  8. Super Session
    Fireside Chat with Nauman Shah, Global Head of Business Development, Johnson & Johnson Innovative Medicine
    Super Session
    • Business Development and Finance
    28ABCDE
    johnson and johnson
    Nauman Shah
    Nauman Shah, Global Head of Business Development - Johnson & Johnson Innovative Medicine
  9. Lessons from the Oregon Trail: Pioneering Gene Therapy in the Real World
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Tom Klima
    Tom Klima, Chief Operating and Commercial Officer - bluebird bio
    Joe Garrity
    Joe Garrity, Senior Director, Head of Autologous Cell Therapy - Lonza
    Tim Olson
    Tim Olson, Medical Director, Blood and Marrow Transplant Program - Children's Hospital of Philadelphia
    Michelle Campbell
    Michelle Campbell, Caregiver - N/A
    Kirk Davis
    Kirk Davis, Cigna Healthcare Gene Therapy Program, Senior Manager - Cigna
  10. The Cross-Border Applicability of RWD in Decision-Making
    Breakout Session
    • Regulatory Innovation
    31C
    Rachel Ehlers
    Rachel Ehlers, Partner - Baker McKenzie
    Michele Colucci
    Michele Colucci, Founder & Managing Partner - DigitalDx Ventures
    Michelle Wong
    Michelle Wong, Head of Operations - Octant
    Jonathan Fairtlough
    Jonathan Fairtlough, Principal - KPMG
    Virginia Sanzone
    Virginia Sanzone, General Counsel - ICU Medical
  11. The Time is Now: Global Perspectives on Preparing for Public Health Emergencies
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Emergent logo
3:00 PM – 4:00 PM
(PST)
  1. A New Era for Access and Affordability: Considerations for Patients and Manufacturers in a Post-IRA World
    Breakout Session
    • Patient Advocacy
    26A
    Mark Gooding
    Mark Gooding, Managing Director - Avalere
    Anna Hyde
    Anna Hyde, Vice President of Advocacy and Access - Arthritis Foundation
    Valerie Reynolds
    Valerie Reynolds, Executive Director - Genentech
  2. A Perspective from the Trenches: Challenges of Budgeting for Gene Therapies, Innovative Payment Systems That Work for Medicaid Departments and Patients, and What the States Need from CMS
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Thomas Barker
    Thomas Barker, Partner - Foley Hoag LLP
    Scott McGoohan
    Scott McGoohan, Executive Director, Policy and Alliance Development - Vertex Pharmaceuticals
    Jay Newman
    Jay Newman, SVP, Commercial Development, Pricing & Reimbursement - Spark Therapeutics, Inc.
  3. AI and Regulatory Innovation in Healthcare: Shaping the Future
    Breakout Session
    • Regulatory Innovation
    31C
    Paul Howard
    Paul Howard, Senior Director of Public Policy - Amicus Therapeutics
    Lina Nilsson
    Lina Nilsson, VP of Product - Recursion
    Meredith Brown-Tuttle
    Meredith Brown-Tuttle, Chief Regulatory Strategist - Regulatorium
    Shlomo Klapper
    Shlomo Klapper, COO - Weave
  4. An Insider Look at Top Deals from 2023
    Breakout Session
    • Business Development and Finance
    29AB
    Carin Canale-Theakston
    Carin Canale-Theakston, CEO - Evoke Canale
    Mark McKenna
    Mark McKenna, CEO - Mirador Therapeutics
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
  5. Biotech Beyond Borders: Emerging Stronger from a Complex Macroenvironment
    Breakout Session
    • Business Development and Finance
    32AB
    Arda Ural
    Arda Ural, Americas Life Sciences Sector Leader - EY (Ernst & Young)
    Chris Garabedian
    Chris Garabedian, VC Portfolio Manager - Perceptive Advisors
    Barbara Ryan
    Barbara Ryan, Board Member, Senior Advisor to EY, Indivior, Mink, Invo, SafeCor Pharmaceutical Companies
    Brian Bronk
    Brian Bronk, Global Head of Business Development, Neurology, Rare Diseases & Technology Platforms - Sanofi
    Julie Rozenblyum
    Julie Rozenblyum, Senior Vice President, Business Development - BMS
  6. Emerging Technologies Fostering Biotech Innovation Globally
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Falk Ehmann
    Falk Ehmann, Head of Innovation and Development Accelerator (IDeA) - European Medicines Agency (EMA)
    Blythe Adamson
    Blythe Adamson, Senior Principal Scientist, Head of Outcomes Research - Flatiron Health
    Lesley Maloney
    Lesley Maloney, Global Regulatory Policy Lead for Digital Health - Genentech, Inc., A Member of the Roche Group
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Robert Schroeder
    Robert Schroeder, Head of External Communications - European Innovation Council and SMEs Executive Agency (EISMEA)
    Mahesh Yadav
    Mahesh Yadav, Distinguished Scientist - Genentech
  7. Fireside Chat
    Fireside Chat with Nina Kjellson, General Partner, Canaan Partners
    Fireside Chat
    • Business Development and Finance
    30DE
    Nina Kjellson
    Nina Kjellson, General Partner - Canaan Partners
  8. Fireside Chat
    Fireside Chat with Stephen Quake, Head of Science, Chan Zuckerberg Initiative
    Fireside Chat
    • Next Generation Biotherapeutics
    25ABC
    Steve Quake
    Steve Quake, Head of Science - Chan Zuckerberg Initiative
  9. Forging New Pathways to Reimbursement for Digital Therapeutics: Considerations for Payer Coverage
    Breakout Session
    • AI and Digital Health
    24BC
    Brigit Kyei-Baffour
    Brigit Kyei-Baffour, Principal - Avalere
    Mona Chitre
    Mona Chitre, Pharmacy Officer and President of Pharmacy Solutions - Excellus BlueCross BlueShield
    Jon Campbell
    Jon Campbell
  10. Global Policy Perspectives on the Next Generation of Rare Disease Medicines
    Breakout Session
    • Orphan and Rare Disease
    28ABCDE

    merck logo

    Jannie Oosthuizen
    Jannie Oosthuizen, President - Merck
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Policy and Regulatory Affairs - National Organization for Rare Disorders (NORD)
  11. Let’s Go STEDI: Moving Beyond QALY’s to Understand the True Value of Antimicrobials and Vaccines
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Ted Buckley
    Ted Buckley, Vice President, Government Affairs - Shionogi
    John Rex
    John Rex, Chief Medical Officer - F2G
    Scott Johnson
    Scott Johnson, CEO/Founder - Medicus Economics
    Ella Balasa
    Ella Balasa, Patient Expert - Balasa Consulting
  12. Longevity Therapeutics Enter Biopharma Mainstream
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Brian Gormley
    Brian Gormley, Reporter - Wall Street Journal
    Marco Quarta
    Marco Quarta, Founder and CEO - Rubedo Life Sciences
    Robert Gould
    Robert Gould, Operating Partner - Khosla Ventures
    Simone Fantaccini
    Simone Fantaccini, Chief Scientific Officer & Head of Medical Affairs - Novartis
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Hanadie Yousef
    Hanadie Yousef, Chief Executive Officer and Co-Founder - Juvena Therapeutics
  13. Patients Wait Less: Streamlining Regulatory Pathways for Cell/Gene Therapies in Asia-Pacific Region
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Pi-Sheng Wang
    Pi-Sheng Wang, Deputy Minister - Ministry of Health and Welfare
    Akira Sakurai
    Akira Sakurai, Deputy Reviewer Director - Pharmaceuticals and Medical Devices Agency
    Yueh-Ping Liu
    Yueh-Ping Liu, Director-General - Department of Medical Affairs, Ministry of Health and Welfare
    Maggie Ho
    Maggie Ho, General Manager, Asian Business & CMC Regulatory Development - Amarex Clinical Research, LLC
    Joseph Damond
    Joseph Damond, Chair of Health Policy - Edelman Global Advisory
4:15 PM – 5:15 PM
(PST)
  1. Agile Biologics Development and Manufacturing Strategies to Meet Market Demand
    Breakout Session
    • Business Development and Finance
    30DE
    thermofisher scientific
  2. Altering the Regulatory Ecosystem for Pediatric Clinical Programs: Intended and Unintended Consequences
    Breakout Session
    • Regulatory Innovation
    31C
    Catherine Lee
    Catherine Lee, Associate Director, Global Regulatory Policy and Intelligence - Johnson & Johnson
    Laurie Conklin
    Laurie Conklin, Senior Director, Pediatric Development - Johnson & Johnson
    Dionna Green
    Dionna Green, Director, Office of Pediatric Therapeutics - FDA
    Thomas Miller
    Thomas Miller, Global Head, Acute, Chronic & Pediatric Disease Nucleus - Bayer
  3. Avoid the Cycle of “Panic and Neglect": How Ongoing Commitment to Innovative Partnerships Futureproofs Against the Next Pandemic
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Paul Friedrichs
    Paul Friedrichs, Director - Office of Pandemic Preparedness and Response Policy (OPPR)
    Georges Benjamin
    Georges Benjamin, Executive Director - American Public Health Association
    Robert Walker
    Robert Walker, Senior Vice President and Chief Medical Officer - Novavax, Inc.
    Laurent Muschel
    Laurent Muschel, Acting Director General - European Commission, Health Emergency Preparedness and Response Authority (HERA)
    Emma Wheatley
    Emma Wheatley, Director, Access and Private Partnerships - CEPI
  4. Creative Structures for Keeping Innovation Alive After the Deal
    Breakout Session
    • Business Development and Finance
    29AB
    Oren Livne
    Oren Livne, Partner - Baker McKenzie
    Gavin Liu
    Gavin Liu, Senior Director, Legal Strategic Transactions - Astellas
    Paul van der Horst
    Paul van der Horst, Chief Business Officer - AgomAb Therapeutics
    Deepa Talpade
    Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
  5. Fireside Chat
    Fireside Chat with Matt Gline, CEO, Roivant Sciences
    Fireside Chat
    • Business Development and Finance
    25ABC
    Michelle Davis
    Michelle Davis, M&A Reporter - Bloomberg News
    Matt Gline
    Matt Gline, Chief Executive Officer - Roivant Sciences
  6. From Patients to Partners: Patient Advocacy and Biotech Collaborate to Accelerate Innovation
    Breakout Session
    • Patient Advocacy
    26A
    Anthony Mancini
    Anthony Mancini, EVP & Chief Operating Officer - Genmab
    Meghan Gutierrez
    Meghan Gutierrez, CEO - Lymphoma Research Foundation
    Portia Badham
    Portia Badham
  7. Gun Violence Prevention: A Case Study in Passing Meaningful Policies in a Hyper Partisan Era
    Special Program
    • Regulatory Innovation
    28ABCDE
    Josh Horwitz
    Josh Horwitz, Co-director - Johns Hopkins Center for Gun Violence Solutions
    Angus McQuilken
    Angus McQuilken, Life Sciences Industry Relationship Executive - McDermott Will & Emery
    Jen Pauliukonis
    Jen Pauliukonis, Director of Policy and Programming - Johns Hopkins Center for Gun Violence Solutions
    Traci Murphy
    Traci Murphy, Executive Director - Coalition for a Safer Delaware
  8. Innovation Passport: Emerging Opportunities for Company Growth in Global Markets
    Breakout Session
    • Business Development and Finance
    32AB
    Susie Harborth
    Susie Harborth, Chief Business Officer - Breakthrough Properties
    Bernard Parker
    Bernard Parker, Chief Business Officer - Shanghai Pharma Biotherapeutics USA, Inc.
    Avi Spier
    Avi Spier, Executive Director Business Development and Licensing - Novartis
    Kristen Albright
    Kristen Albright, CEO - Prokarium
    Wen Qi Ho
    Wen Qi Ho, Therapeutics Lead - ClavystBio
  9. Investors' Perspectives: Digital Health Trends and Investment Thesis in 2024 and Beyond
    Breakout Session
    • AI and Digital Health
    24BC
    Josh Seidenfeld
    Josh Seidenfeld, Partner and Chair, Digital Health - Cooley LLP
    Sourav Kole
    Sourav Kole, Managing Director - Dolby Family Ventures
    Mara Aspinall
    Mara Aspinall, Partner - Illumina Ventures
  10. Quality Standards for Final Preparation of CGT Product at Point of Care (POC)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Maria Amaya
    Maria Amaya, Lead External Advocacy, Quality Policy and Advocacy - Genentech, A member of the Roche Group
    Lesbeth Rodriguez
    Lesbeth Rodriguez, Director, Regulatory Affairs, Policy and Innovation - Bayer
    Maria Sørensen
    Maria Sørensen, Specialist, RA CMC Lead - Novo Nordisk
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Heather Lombardi
    Heather Lombardi, Director, Office of Cellular Therapy and Human Tissue - FDA
  11. Unlocking Biotech Growth: Hong Kong as the Gateway to Global Markets
    Breakout Session
    • Asia-Pacific Opportunities
    30ABC
    Albert Wong
    Albert Wong, CEO - Hong Kong Science and Technology Parks Corporation
    Grace Lau
    Grace Lau, Head of Institute for Translational Research - Hong Kong Science and Technology Parks Corporation
    Andy Wong
    Andy Wong, Head of Innovation and Technology - Invest Hong Kong
    Michael Chen
    Michael Chen, CEO & Co-founder - Great Bay Bio Limited
    Gaobo Zhou
    Gaobo Zhou, Chief Investment Officer - Simcere Pharmaceutical Group Limited
  12. Unlocking Success to Biotech Global Expansion: A Stepwise Game Plan for International Launch
    Breakout Session
    • Emerging Opportunities in Global Markets
    26B
    Eduardo Schur
    Eduardo Schur, US Health Sciences & Wellness Commercial Strategy and R&D Lead - EY
    Tolga Tanguler
    Tolga Tanguler, CCO - Alnylam Pharmaceuticals
    Russell Cox
    Russell Cox, President & CEO - Epirium Bio
    Robert LaCaze
    Robert LaCaze, CEO - Mnemo Therapeutics
    Ger Brophy
    Ger Brophy, Chair of the Scientific Advisory Board and retiring EVP Biopharma Production - Avantor
    Jérôme Revole
    Jérôme Revole, Managing Director Healthcare and Lifesciences - Business France North America
  13. Use of AI in mRNA: The New Revolution?
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Andy French
    Andy French, Director, Data & AI - CGI
    Mathieu Blanchette
    Mathieu Blanchette, Director - McGill University
    Christian Barrow
    Christian Barrow, Executive Director - J.P. Morgan
    Petrina Kamya
    Petrina Kamya, Vice President and Global Head of AI Platforms, Insilico Medicine - President, Insilico Medicine Canada
    Andrew Giessel
    Andrew Giessel, Executive Director - Moderna
7:00 PM – 9:00 PM
(PST)
  1. Welcome Reception
    Session
6:30 AM – 6:30 PM
(PST)
  1. Registration
    Session
  2. Registration - Marriott Marquis Satellite Location
    Session
10:30 AM – 4:10 PM
(PST)
  1. Overcoming Development, Scale Up and Commercial Production Challenges for Novel Modalities
    BioProcess BioProcess Theater
  2. Welcome Session: BioProcess Insider
    BP BioProcess Theater
    Dan Stanton
    Dan Stanton, Founder and Managing Editor - BioProcess Insider
11:00 AM – 12:00 PM
(PST)
  1. AI's Trial by Fire: Experimental Validation in Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Nitya Sridhar
    Nitya Sridhar - Power
    Martin Akerman
    Martin Akerman, Co-founder and CTO - Envisagenics
    Alex Zhavoronkov
    Alex Zhavoronkov, Founder and CEO - InSilico Medicine
    Michael Bembem
    Michael Bembem, Director, Data Science and External Innovation - Johnson & Johnson
    Etai Jacob
    Etai Jacob, Senior Director, Head of Data Science and AI, Early Oncology - AstraZeneca
    Stacie Calad Thomson
    Stacie Calad Thomson, Vice Chairperson - Alliance for AI in Healthcare (AAIH)
  2. Avoiding Commercialization Pitfalls for Cell and Gene Therapies
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    30ABC
    cencora
    Lung-I Cheng
    Lung-I Cheng
  3. Brick-by-Brick: Building a Biotech from Foundation Up with Venture Investor Company Formation
    Breakout Session
    • Business Development and Finance
    26B
    Allison DeAngelis
    Allison DeAngelis, Reporter - STAT News
    Ann Lee-Karlon
    Ann Lee-Karlon, Chief Executive Officer and President - EpiBiologics
    Jay Parrish
    Jay Parrish, Chairman and Chief Executive Officer - Pretzel Therapeutics
    Amy Liu
    Amy Liu, Investor - Mubadala Capital
    Mitchell Mutz
    Mitchell Mutz, Entrepreneur Partner - Vivo Capital
    Sanjay Mistry
    Sanjay Mistry, Vice President - Johnson & Johnson Innovation
  4. Build Your Product Pipeline with Non-Dilutive Federal Resources
    Breakout Session
    • Business Development and Finance
    29AB
    Stephanie Fertig
    Stephanie Fertig, Director, NIH Small Business Program - National Institutes of Health (NIH)
    Elaine Haynes
    Elaine Haynes, President and CEO - KaloCyte, Inc.
    Julius Korley
    Julius Korley, Associate Vice President, Office of Economic Innovation and Partnerships - University of Delaware
    Meghan Wood
    Meghan Wood, Managing Director - New York Blood Center Ventures
  5. Building a Bioscience Economy Through Supportive State Legislation: A Discussion with State Legislators from California, Massachusetts, and the Midwest
    Special Program
    • Regulatory Innovation
    29C
  6. Case Studies: Advancing Next Generation Modalities To Market
    BP BioProcess Theater
  7. FDA Townhall
    Special Program 25ABC
    Patrizia Cavazzoni
    Patrizia Cavazzoni, Director, Center for Drug Evaluation and Research - FDA
    Peter Marks
    Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) - U.S. Food and Drug Administration
  8. In and Out of This World: Partnering with Federal Labs
    Breakout Session
    • Business Development and Finance
    32AB
    Vladimir Popov
    Vladimir Popov, Chief Innovation Officer - Frederick National Laboratory for Cancer Research
    Edward Diehl
    Edward Diehl, Commercialization Officer - U.S. Army Medical Research and Development Command
    Tara Kirby
    Tara Kirby, Director of the Office of Technology Transfer - National Institute of Health
    Michael Roberts
    Michael Roberts, Chief Scientific Officer - International Space Station National Laboratory
    Gillian Fenton
    Gillian Fenton, Vaccines Legal Operations - GSK
    Lisa Thomas Read
    Lisa Thomas Read, Vice President, Research and Development - Amivas (US), LLC
  9. New Pain Therapeutics: Strategies for Innovation, Investment, and Collaboration
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Hernan Bazan
    Hernan Bazan, CEO & Co-Founder - South Rampart Pharma, Inc.
    Emily Caporello
    Emily Caporello, Program Director, Division of Translational Research - NINDS, NIH
    Paige Cramer Lacatena
    Paige Cramer Lacatena, Director Business Development and Licensing, HQ Neurology - Merck
    Ana Moreno
    Ana Moreno, CEO and Founder - Navega Therapeutics
    Paul Mieyal
    Paul Mieyal, Managing Director - Outcome Capital, LLC
    Todd Bertoch
    Todd Bertoch, Chief Executive Officer at JBR Clinical Research - CenExel
  10. Strengthening of the Clinical Trials Environment in Europe Under the Accelerating Clinical Trials (ACT EU) Initiative
    Breakout Session
    • Clinical Trials Innovations
    31C
    Laura Pioppo
    Laura Pioppo, ACT EU Programme manager - European Medicines Agency (EMA)
    Claire Skentelbery
    Claire Skentelbery, Director General - EuropaBio
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
  11. Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics
    Breakout Session
    • Brain Health
    26A
    Alaa Halawa
    Alaa Halawa, Executive Director and Head of Healthcare, US Ventures - Mubadala Capital
    Carol Suh
    Carol Suh, Co-founder & Chief Operating Officer - Neumora
    Joanne Taylor
    Joanne Taylor, Senior Vice President, Research - Gain Therapeutics
    Richard Shea
    Richard Shea, CEO - Basking Biosciences
    Craig Thompson
    Craig Thompson, CEO - Cerevance
12:00 PM – 12:10 PM
(PST)
  1. BioProcess Insider Interviews: Samsung Biologics
    BP BioProcess Theater
12:10 PM – 12:20 PM
(PST)
  1. Insider Interviews
    BP
12:15 PM – 1:30 PM
(PST)
  1. Super Session
    Where to Launch? Expanding Beyond Home and Activating Your Product’s Global Potential
    Super Session
    • Emerging Opportunities in Global Markets
    28ABCDE
    Sandra Anderson
    Sandra Anderson, Senior Vice President - Cencora
12:20 PM – 1:00 PM
(PST)
  1. The Manufacturing Make vs. Buy Decision for Cell and Gene Therapies: Implications for Overcoming Manufacturing Bottlenecks and Challenges
    BP BioProcess Theater
    Stephen Orosz
    Stephen Orosz, Managing Director - BDO
1:00 PM – 1:30 PM
(PST)
  1. Industry Case Study: Achieving Quality Yields For The Next Generation of Antibody/Bispecific/ Cell & Gene Product
    BP
1:30 PM – 2:45 PM
(PST)
  1. Industry Case Study: Virtual reality software for molecular modeling and collaborative drug design
    BP
    Steve McCloskey
    Steve McCloskey
  2. Student Program: An Introduction to the Biotechnology Industry
    Special Program 29AB
1:45 PM – 2:45 PM
(PST)
  1. Accelerating the Globalization of Cell and Gene Therapies
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Jennifer Rabin
    Jennifer Rabin, Specialist Leader - Deloitte Consulting LLP
    Sumant Ramachandra
    Sumant Ramachandra, CEO - Impact Bio
    Shahrukh Hashmi
    Shahrukh Hashmi, Faculty - Mayo Clinic
    Kristen Sudol
    Kristen Sudol
    Fabian Gerlinghaus
    Fabian Gerlinghaus, CEO - Cellares
    Robert Hughes
    Robert Hughes
  2. AI/ML is Transforming R&D and Business
    Breakout Session
    • AI and Digital Health
    24BC
    Maude Tessier
    Maude Tessier, Chief Business Officer - Seismic Therapeutic
    Jiye Shi
    Jiye Shi, Vice President - Eli Lilly
    Joe McDonald
    Joe McDonald, Chief Data Officer - Odyssey Therapeutics
  3. Creative Claiming for Platforms & Products: Designing an IP Strategy to Go Global
    Breakout Session
    • Intellectual Property
    26B
    Tanis Keirstead
    Tanis Keirstead, Partner - Mewburn Ellis
    Robin Silva
    Robin Silva, Vice President of Intellectual Property - Xencor, Inc.
    Malathi Lakshmikumaran
    Malathi Lakshmikumaran, Executive Director and Practice Head - Lakshmikumaran & Sridharan
    Yoon Suk SHIN
    Yoon Suk SHIN, Senior Partner/Patent Attorney - Lee International IP & Law
    Amy Feng
    Amy Feng, Managing Partner - Wu, Feng & Zhang
  4. Fireside Chat
    Fireside Chat with Robert A. Bradway, Chairman and Chief Executive Officer, Amgen
    Fireside Chat
    • Business Development and Finance
    25ABC
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    Robert Bradway
    Robert Bradway, Chief Executive Officer and Chairman - Amgen
  5. Growth Opportunities from Women’s Health Investments
    Breakout Session
    • Business Development and Finance
    30DE
    Sheila Mikhail
    Sheila Mikhail, Board Member, Women's Health Access Matters; Executive Director - BC Ruckus
    Heather Bowerman
    Heather Bowerman, CEO & Founder - DotLab
    Lucy Pérez
    Lucy Pérez, Senior Partner - McKinsey & Company
    Stasia Obremskey
    Stasia Obremskey, Managing Director - RH Capital
    Mary Beth Cicero
    Mary Beth Cicero, Co-Founder and CEO - 3Daughters
  6. Joining Forces to Accelerate Innovation in Oncology
    Breakout Session
    • Oncology
    30ABC
    Genentech logo
    Visali Ramanathan
    Visali Ramanathan, Executive Director - Genentech
    Gregor Fachinger Fachinger
    Gregor Fachinger Fachinger, VP, Head of Oncology & Immuno-Oncology Business Development - Merck KGaA
    Susan Graf
    Susan Graf, Biotech Executive, Board Member & Advisor
  7. NIH Support for Minority Health and Health Disparities Focused on Early-Stage Life Science Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Michael Banyas
    Michael Banyas, Program Manager - National Institute of Minority and Health Disparities
    Dave Whelan
    Dave Whelan, Managing Director - Bespoke Strategies
    Corine Farewell
    Corine Farewell, Director UVM Innovations - University of Vermont
    Anna Lisa Somera
    Anna Lisa Somera, CEO - Rhaeos
    Ke Zhang
    Ke Zhang, Founder and interim CEO - Allerdia Inc.
  8. Partnering with CROs and their High-Value Network of Providers to Drive Speed, Cost Effectiveness and Quality in your Clinical Development
    Breakout Session
    • Business Development and Finance
    23BC
    fortrea logo
    Tom Pike
    Tom Pike, Chairman and Chief Executive Officer - Foretrea
    Jennifer Byrne
    Jennifer Byrne, Founder and CEO - Javara
    Michael Norton
    Michael Norton, Senior Advisor - Boston Consulting Group
    Gadi Saarony
    Gadi Saarony, CEO - Advarra
  9. Promising Advances in Neuroscience: New Molecular Targets and Biomarkers
    Breakout Session
    • Brain Health
    26A
    Hank Safferstein
    Hank Safferstein, Senior Advisor - UPMC Enterprises
    Susanne Ahmari
    Susanne Ahmari, Assistant Professor, Department of Psychiatry - University of Pittsburgh
    Amit Etkin
    Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Maha Radhakrishnan
    Maha Radhakrishnan, Chief Medical Officer - Biogen
  10. Strategies for Antimicrobial Access in LMICs
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Jomana Musmar
    Jomana Musmar, Executive Director of the Presidential Advisory Council for Combating Antibiotic - Resistant Bacteria (PACCARB)
    Monika Schneider
    Monika Schneider, Director, Global AMR Policy - Shionogi
    Kevin Outterson
    Kevin Outterson, Executive Director - CARB-X
    Yann Ferrisse
    Yann Ferrisse, Business Development & Partner Engagement Director - GARDP Foundation
  11. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
    Special Program
    • Business Development and Finance
    32AB
    David Thomas
    David Thomas, Senior Vice President, Industry Research - Biotechnology Innovation Organization (BIO)
2:00 PM – 3:00 PM
(PST)
  1. BioProcess Insider Focus
    BP
3:00 PM – 4:00 PM
(PST)
  1. Breaking the Cycle: Innovations in Addressing Substance Use Disorder
    Breakout Session
    • Brain Health
    26A
    Tam Nguyen
    Tam Nguyen, Program Officer - National Institute on Drug Abuse (NIDA)
    Courtney Miller
    Courtney Miller, Founder, Myosin Therapeutics; Professor Department of Molecular Medicine, Department of Neuroscience - UF Scripps Biomedical Research
    Joanne Peterson
    Joanne Peterson, Founder and Executive Director - Learn to Cope
    James Hickman
    James Hickman, Professor of NanoScience, Chemistry, Biomolecular Science, Physics and Electrical Engineering, University of Central Florida; Chief Scientist - Hesperos
  2. Building a More Sustainable Biopharma Innovation Ecosystem
    Breakout Session
    • Environmental Sustainability
    29C
    Rachel Kaufman
    Rachel Kaufman, Head of Global Sustainability - Avantor
    Joydeep Ganguly
    Joydeep Ganguly, Senior Vice President of Corporate Operations, and Chief Sustainability Officer - Gilead Sciences
    Mark Steen
    Mark Steen, VP, Sustainability and Climate Initiatives - Corning
  3. Case Studies: Advancing Next Generation Modalities To Market
    BP
  4. Fireside Chat
    Fireside Chat with Joshua Boger, PhD, Founder and Former CEO of Vertex Pharmaceuticals; Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
    Fireside Chat
    • Business Development and Finance
    25ABC
    Joshua Boger
    Joshua Boger, Founder and Former CEO of Vertex Pharmaceuticals - Executive Chairman, Alkeus Pharmaceuticals; Chair of Board, CervoMed
  5. From Incubation to Acquisition: The Growth Journey of an Early-Stage Company
    Breakout Session
    • Business Development and Finance
    30ABC
    johnson and johnson
    Melinda Richter
    Melinda Richter, Global Head - Johnson & Johnson
    Matt Lorenzi
    Matt Lorenzi, Vice President - Johnson & Johnson
    Colin Farlow
    Colin Farlow, Co-Founder and CEO - Serotiny
    Eric Moessinger
    Eric Moessinger, Partner - +ND Capital
    Leo MacDonald
    Leo MacDonald, Vice President - Johnson & Johnson Innovative Medicine
  6. Getting Personal: How the Evolving U.S. Privacy Legal Landscape Impacts Biomedical Research
    Breakout Session
    • AI and Digital Health
    24BC
    Justin Pine
    Justin Pine, Senior Director - Biotechnology Innovation Organization (BIO)
    Kimberly Gold
    Kimberly Gold, Chief Privacy Officer - Genentech
  7. Microgravity: A Strategic Advantage in R&D
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Elizabeth Reynolds
    Elizabeth Reynolds, Managing Director - Starburst Aerospace
    Kate Rubins
    Kate Rubins, Astronaut - NASA
    Paul Reichert
    Paul Reichert, Associate Principal Scientist - Merck
    Rob Garmise
    Rob Garmise, Director of Formulations Development, Exploratory Biopharmaceutics - Bristol Myers Squibb
  8. Optimizing the Investability of Your Lead Program: Data-Driven Approaches for Pipeline Prioritization
    Breakout Session
    • Business Development and Finance
    32AB
    Drew Cutshaw
    Drew Cutshaw, Senior Associate, Medical Officer - Pappas Capital
    Mike Grey
    Mike Grey, Chairman - Plexium
    Susan Lenderts
    Susan Lenderts, Head of Life Sciences - SAS Institute, INC
    Ben Davis
    Ben Davis, Vice President, Corporate Alliances - IQVIA
  9. Preparing for Platforms: Sponsor and Regulator Perspectives on the Platform Technology Designation (PTD)
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Dylan Bechtle
    Dylan Bechtle, US Regulatory Policy Lead - Johnson & Johnson
    Snehal Naik
    Snehal Naik, Head of Regulatory Policy - Spark Therapeutics
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Anne-Virginie Eggimann
    Anne-Virginie Eggimann, Chief Regulatory Officer - Tessera Therapuetics
    Antonella Lozito
    Antonella Lozito, Executive Director, Regulatory Affairs, Infectious Disease - Moderna
    Nicole Verdun
    Nicole Verdun, Super Office Director, CBER - FDA
  10. Super Session
    Superconvergence: How the AI, Genetics, and Biotechnology Revolutions Will Transform our Lives, Work, and World
    Super Session
    • Next Generation Biotherapeutics
    28ABCDE
    Jamie Metzl
    Jamie Metzl, Founder and Chair - OneShared.World
  11. The Bad and the Ugly: Unpacking Repercussions of the Medicaid Drug Rebate Program Rule
    Breakout Session
    • Business Development and Finance
    29AB
    John Murphy
    John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)
    Matt Salo
    Matt Salo, CEO - Salo Health Strategies
    Pete Norman
    Pete Norman, Senior Vice President - Alkermes, Inc.
    Alice Valder Curran
    Alice Valder Curran, Partner - Hogan Lovells
  12. Workforce, Diversity, Equity, and Inclusion at BIO: Presenting New Survey Data and Exploring Partnerships
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Ted Love
    Ted Love, Chair - BIO Board of Directors
    Charlotte Jones-Burton
    Charlotte Jones-Burton, Founder - Women of Color in Pharma
    Mark Royal
    Mark Royal, Senior Client Partner - Korn Ferry
    Jane Barry-Moran
    Jane Barry-Moran, Managing Director, Programs & Research - Out Leadership
3:20 PM – 3:40 PM
(PST)
  1. BioProcess Insider Interviews
    BP
3:40 PM – 4:10 PM
(PST)
  1. KEYNOTE Industry Case Study: Gene Editing Technologies: The Future of Personalized Medicine
    BP
    Nathan Lewis
    Nathan Lewis, Professor of Pediatrics and Bioengineering - University of California San Diego
4:15 PM – 5:15 PM
(PST)
  1. Adaptive Reuse: Biomanufacturing Enters A New Age
    Breakout Session
    • Environmental Sustainability
    29C
    Matt Gardner
    Matt Gardner, Board Chairman - California Biomanufacturing Center
    TJ Silvey
    TJ Silvey, Director - Raymond James
    Ella Woger-Nieves
    Ella Woger-Nieves, CEO - Invest Puerto Rico
    Gordon Zagar
    Gordon Zagar, President & Founder - ZCI
    Ann-Stewart Patterson
    Ann-Stewart Patterson, Executive Vice President - CBRE
  2. AI-Generated Invention and the Future of Bio R&D
    Breakout Session
    • Intellectual Property
    26B
    Hans Sauer
    Hans Sauer, Deputy General Counsel, VP for IP - Biotechnology Innovation Organization (BIO)
    Ryan Abbott
    Ryan Abbott, Partner - Brown, Neri, Smith & Khan, LLP
    Andrei Iancu
    Andrei Iancu, Partner - Sullivan & Cromwell LLP
    Sarah Korman
    Sarah Korman, General Counsel - Isomorphic Labs
  3. Becoming an Early Innovation Partner of Choice
    Breakout Session
    • Business Development and Finance
    29AB
    David Kane
    David Kane, Managing Partner - Arc Bio Communications
    Helena Chaye
    Helena Chaye, CEO - KaliVir
    Peter Sandor
    Peter Sandor, Senior Vice President, Primary Focus Lead, Primary Focus Immuno-oncology - Astellas Pharma
    Olga Granaturova
    Olga Granaturova, CEO - PrivBio
    Anna Chen
    Anna Chen, Principal - Frazier Life Sciences
  4. Best Practices for Managing Your Biotech’s Ca$hflow
    Breakout Session
    • Business Development and Finance
    32AB
    Joel Papernik
    Joel Papernik, Member - Mintz
    Barbara Wood
    Barbara Wood, Executive Vice President, General Counsel and Corporate Secretary - Sellas Life Sciences
    Robert Van Nostrand
    Robert Van Nostrand, Board of Directors Member - Intra-Cellular Therapies
    Heidi Henson
    Heidi Henson, Director - Lisata Therapeutics
    Robert Easton
    Robert Easton - Eastern Strategy, LLC
  5. Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation
    Breakout Session
    • Brain Health
    26A
    Heather McKenzie
    Heather McKenzie, Senior Editor - BioSpace
    Laxminarayan Bhat
    Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc
    Amit Etkin
    Amit Etkin, Founder and Chief Executive Officer - Alto Neuroscience
    Daniel Karlin
    Daniel Karlin, Chief Medical Officer - Mind Medicine (MindMed)
    David Benshoof Klein
    David Benshoof Klein, Co-Founder and CEO - Click Therapeutics
  6. Exploring the Future of Gene Delivery: A Conversation on the Direction for Next-Generation Vectors
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    31AB
    Ola Tuvesson
    Ola Tuvesson, Chief Technology Officer - NorthX Biologics
    Johan Rockberg
    Johan Rockberg, Professor at the Royal Institute of Technology and Director of GeneNova - Royal Institute of Technology
    Peter de Haan
    Peter de Haan, Founder and Chief Scientific Officer - Amarna Therapeutics BV
    Amy Walker
    Amy Walker, Vice President of Research and Business Development - 4BaseBio PLC
  7. Exploring the Uncharted: Rare Diseases, Unintended Consequences of the Inflation Reduction Act, and Demonstrating the Value of These Therapies
    Breakout Session
    • Orphan and Rare Disease
    30DE
    alexion logo
    John Murphy
    John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)
  8. Super Session
    Fireside Chat with John McDonald, Corporate Vice President, Global Head of Business Development and M&A
    Super Session
    • Business Development and Finance
    28ABCDE
    novo nordisk
    John McDonald
    John McDonald, Corporate Vice President - Novo Nordisk
  9. Future of Biopharma Innovation: Unleashing the Potential of Emerging Therapeutic Modalities in Oncology and Beyond
    Breakout Session
    • Next Generation Biotherapeutics
    23BC
    Romain Bonnot
    Romain Bonnot, Principal - ZS Associates
    Jesper Haaning
    Jesper Haaning, Head of Development External Innovation - Novo Nordisk
    Lucas Donigian
    Lucas Donigian, Executive Director, Business Development - Zymeworks Inc.
    Malik Kaman
    Malik Kaman, Principal - ZS Associates
  10. Highlighting the Power of Patient Organizations: Exploring Initiatives That Drive Equitable Impact for Patients and Communities
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Deepa Dahal
    Deepa Dahal, Co-founder and Partner - DKI Health. LLC
    Mary Stutts
    Mary Stutts, Chief Executive Officer - Healthcare Businesswomen's Association
    Joseph Nadglowski
    Joseph Nadglowski, President and Chief Executive Officer - Obesity Action Coalition
    Christine Verini
    Christine Verini, CEO - CancerCare
    Sonali Chopra
    Sonali Chopra, Executive Director, Patient Advocacy Relations - Genentech a Member of the Roche Group
  11. The Future of Immunology: Path to Precision Medicine
    Breakout Session
    • Diagnostics and Personalized Medicine
    24BC

    merck logo

    Max Bayer
    Max Bayer, Staff Reporter - Fierce Biotech
    Aileen Lorenzo Pangan
    Aileen Lorenzo Pangan, Vice President & Therapeutic Area Head - Merck
    Cynthia Bens
    Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
    Stephan Targan
    Stephan Targan, Director - Cedars-Sinai, Los Angeles
    Andres Hurtado-Lorenzo
    Andres Hurtado-Lorenzo, Senior Vice President - Crohn's and Colitis Foundation
  12. Fireside Chat
    Thinking Outside the Lab: Lessons from Nobel Laureate Carolyn Bertozzi, PhD, on Building Blockbuster Biotech Companies
    Fireside Chat 25ABC
    Jenny Rooke
    Jenny Rooke, Founder and Managing Director - Genoa Venture
    Carolyn Bertozzi
    Carolyn Bertozzi, Professor of Chemistry - Stanford University
5:00 PM – 6:30 PM
(PST)
  1. Exhibition Reception
    Session
6:30 AM – 7:00 PM
(PST)
  1. Registration
    Session
9:00 AM – 10:30 AM
(PST)
  1. Keynote: Admiral William H. McRaven, U.S. Navy Four-Star Admiral (Retired)
    Keynote
    John Crowley
    John Crowley, President & CEO - Biotechnology Innovation Organization (BIO)
    William McRaven
    William McRaven, U.S. Navy Four-Star Admiral (Retired)
10:30 AM – 4:10 PM
(PST)
  1. Incorporating New Technologies in Development and Production, Regulatory Landscapes, and Agile Manufacturing
    BioProcess BioProcess Theater
  2. Industry Keynote: Integrated Development and Manufacturing Strategy for A Flexible Platform and Facility for Multi-Modal Product Development from Gene Therapy, Vaccine to Mab
    BP
    David Jen
    David Jen, Principal Consultant - Bioblue CMC Manufacturing Consulting LLC
11:00 AM – 12:00 PM
(PST)
  1. Achieving Commercial Success Through the National Institutes of Health's Intramural Research Program
    Breakout Session
    • Business Development and Finance
    32AB
    Michael Salgaller
    Michael Salgaller, Supervisory Specialist, National Cancer Institute Tech Transfer Center - National Institutes of Health (NIH)
    Mark Rohrbaugh
    Mark Rohrbaugh, Special Advisor for NIH Technology Transfer - National Institutes of Health (NIH)
    Margaret Anderson
    Margaret Anderson, Managing Director - Deloitte Consulting LLP
    Jeffery Alexander
    Jeffery Alexander, Director, Innovation Policy - RTI International
    Melissa Bonner
    Melissa Bonner, Chief Scientific Officer - Nvelop Therapeutics
  2. Biotech Partnering in Stormy Seas: Key Insights on Charting a Course to Successful Deal-Making through a Choppy Market
    Breakout Session
    • Business Development and Finance
    29AB
    Kate Hillier
    Kate Hillier, Partner - Cooley LLP
    Barbara Kosacz
    Barbara Kosacz, COO and General Counsel - Kronos Bio
    Brian Cuneo
    Brian Cuneo, Senior Partner - ARCH Venture Partners
    Joseph Baroldi
    Joseph Baroldi, Executive Vice President, Chief Business Officer Ionis Pharmaceuticals - Ionis Pharmaceuticals
    Stacy Feld
    Stacy Feld, Regional Head - Johnson & Johnson Innovation
  3. Breaking the Rare Disease Deadlock through Multi-Stakeholder Collaboration
    Breakout Session
    • Orphan and Rare Disease
    26A
    Niklas Blomberg
    Niklas Blomberg, Executive Director - Innovative Health Initiative
    Annette Bakker
    Annette Bakker, President - Children's Tumor Foundation
    Klaus Romero
    Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Deborah Requesens
    Deborah Requesens, Director, JumpStart Program - Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania
    Claire Skentelbery
    Claire Skentelbery, Director General - EuropaBio
  4. Case Studies: Bioprocessing of the Future
    Session
  5. How to De-Risk Drug Development from the Earliest Stages
    Breakout Session
    • Business Development and Finance
    23BC
    parexel biotech
  6. Open Innovation in Life Sciences, Decades of Experiences, Time to Regroup!
    Breakout Session
    • Translational Research
    31AB
    Junjun Gao
    Junjun Gao, Sr director BD&L - Bayer
    Karen Chandross
    Karen Chandross, Head, Strategic Initiatives and Scientific Relations N.A. • R&D North America - Sanofi
    Florian Montel
    Florian Montel, Head of Open Sciences - Boehringher Ingelheim
    Pamela Hill
    Pamela Hill, Sr. Director, Head of Open Innovation Program - Astra Zeneca
    Vinit Nijhawan
    Vinit Nijhawan, Managing Director - Mass Ventures
  7. Perspectives from Women Powerbrokers
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Joshua Fox
    Joshua Fox, Member - Mintz
    Anna Turetsky
    Anna Turetsky, Principal, Venture Investments - The Mark Foundation for Cancer Research
    Laura Indolfi
    Laura Indolfi, Chief Executive Officer and Co-Founder - PanTher Therapeutics
    Sabrina Johnson
    Sabrina Johnson, President and CEO - Daré Bioscience, Inc.
  8. Post-Guidance Opportunities and Challenges with Prescription Drug Use-Related Software (PDURS)
    Breakout Session
    • AI and Digital Health
    24BC
    Rob Berlin
    Rob Berlin, Head US Regulatory Policy - GSK
    Eva Temkin
    Eva Temkin, Partner - King & Spalding
    Renee Beaver
    Renee Beaver, Director, Corporate Counsel - Otsuka America Pharmaceutical, Inc
  9. Rising to the Challenge of Science Regulation: Ensuring Public Policy Keeps Pace with Innovation Ecosystem
    Breakout Session
    • Environmental Sustainability
    29C
    Alex Menotti
    Alex Menotti, Vice President, Government Affairs, Policy, and Sustainability - LanzaJet
  10. Using AI/ML for Identification and Optimization of Therapeutic Molecules
    Breakout Session
    • AI and Digital Health
    30ABC
    johnson and johnson
    Michal Preminger
    Michal Preminger, Regional Head - Johnson & Johnson Innovation East North America
    Justin Scheer
    Justin Scheer, Vice President, Global Head - Johnson & Johnson Innovative Medicine
    Joe McDonald
    Joe McDonald, Chief Data Officer - Odyssey Therapeutics
    Mark DePristo
    Mark DePristo, CEO and Co-Founder - BigHat Biosciences
12:00 PM – 12:10 PM
(PST)
  1. BioProcess Insider Interviews: KBI
    BP
12:10 PM – 12:20 PM
(PST)
  1. BioProcess Insider Interviews
    BP
12:20 PM – 1:00 PM
(PST)
  1. State of the Industry BioProcess Insider Round Table
    BP
1:00 PM – 1:30 PM
(PST)
  1. Industry Case Study: Latest Analytical Technologies and Approaches for Bioprocessing
    BP
    Kevin Zen
    Kevin Zen, Senior Director - IGM Biosciences
1:30 PM – 2:45 PM
(PST)
  1. Student Program: Entry into Early Careers in Biotechnology
    Special Program 29AB
1:45 PM – 2:45 PM
(PST)
  1. Advancing Innovation: Best Practices for University-Industry Collaboration
    Breakout Session
    • Translational Research
    31AB
    Ed Pagani
    Ed Pagani, Executive Director, Office for External Partnerships, and Assistant VP, External Partnerships - Duke University
    Caroline Lowenthal
    Caroline Lowenthal, Alliance Manager - MIT
    Tari Suprapto
    Tari Suprapto, Director, Search & Evaluation (Western US & Canada) - Novo Nordisk
    Sunita Rajdev
    Sunita Rajdev, Director - Licensing and Strategic Alliances, Life Sciences - Stanford University
    Doug Krafte
    Doug Krafte, Site Head – Durham, North Carolina, and Sr. Vice President, Ion Channels/Transporters - OmniAb
  2. Applied AI & Advanced Automation in Clinical Development
    Breakout Session
    • AI and Digital Health
    30ABC
    propharma
    Bryan Katz
    Bryan Katz, Chief Strategy Officer - ProPharma
  3. Biotech Innovations for Pet Health
    Breakout Session
    • Environmental Sustainability
    29C
    Ellen Carlin
    Ellen Carlin, Vice President - Pathway Policy Group
    Tammie Wahaus
    Tammie Wahaus, CEO - Elias Animal Health LLC
    Dylan Balsz
    Dylan Balsz, CEO - Anivive Lifesciences
    Megan Grether
    Megan Grether, Global Head of Business Development & Licensing, Animal Health - Boehringer Ingelheim Animal Health
  4. Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Elise Simard
    Elise Simard, Speaker Trainer/Coach - LaVoieHealthScience
    Donna LaVoie
    Donna LaVoie, Founder & CEO - LaVoieHealthScience
  5. Cell Therapy Primer
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    23BC
    Kevin Curran
    Kevin Curran, Scientific Advisor and Instructor - BioTech Primer
  6. Changing Clinical Trial Designs in the IRA Environment and Impacts on Stakeholders in Rare and Ultra-Rare Disease Space
    Breakout Session
    • Orphan and Rare Disease
    26A
    Mariia Salova
    Mariia Salova, Senior Consultant - Avalere
    Amy House
    Amy House, Head of Portfolio Strategy - Beacon Therapeutics
    Primal Kaur
    Primal Kaur, Vice President, Global Development - Amgen
    Matthew Klein
    Matthew Klein, Chief Executive Officer and President - PTC Therapeutics
    Mike Stodghill
    Mike Stodghill, Patient Perspective - Mackenzie's Mission
  7. Diversifying the Talent Pipeline: Industry-Recognized Curriculum for a Skilled Workforce
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Vicki Brannock
    Vicki Brannock, Senior Director Workforce Strategy & Innovation - Biocom California Institute
    Scott Eaker
    Scott Eaker, Chief Operations Officer - Prolacta
    Willie Zuniga
    Willie Zuniga, Retired, Former President and Site Head - Grifols Biologicals
    Judith Velasco
    Judith Velasco, Executive Director - Verdugo Workforce Development Board
    Linnea Fletcher
    Linnea Fletcher, Executive Director - InnovATEBIO, National Biotechnology Center
  8. New Tools, New Times: Chemical and Structural AI for Drug Discovery
    Breakout Session
    • AI and Digital Health
    24BC
    Ayman AlAbdallah
    Ayman AlAbdallah, Partner - Mubadala Capital
    Lee Cronin
    Lee Cronin, Founder and Chief Executive Officer - Chemify
    Raphael Townshend
    Raphael Townshend, Founder & CEO - Atomic AI
    Tom Miller
    Tom Miller, CEO and co-founder - Iambic Therapeutics
  9. Pioneering Paths: Navigating the Frontiers of First-in-Class
    Breakout Session 30DE
    bayer
    Seth Ettenbeurg
    Seth Ettenbeurg, President and CEO - BlueRock Therapeutics
  10. The Oncology Endgame: Assemble and Shine with AI and Precision Medicine, or Lose.
    Breakout Session
    • Oncology
    26B
    Karim Budhwani
    Karim Budhwani, CEO-Scientist - CerFlux
    Tahera Kan
    Tahera Kan, Vice President, Head of Precision Medicine - Johnson & Johnson
    Sandeep Menon
    Sandeep Menon, Chief Scientific Officer, AI Digital Sciences and SVP, Head of Early Clinical Development - Pfizer
    Maggie Scully
    Maggie Scully, Partnership Development Director - Frederick National Laboratory for Cancer Research
2:00 PM – 3:00 PM
(PST)
  1. BioProcess Insider Focus
    BP
3:00 PM – 4:00 PM
(PST)
  1. AI's Impact on Oncology Cancer Drug Development
    Breakout Session
    • Oncology
    26B
    Wyatt McDonnell
    Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Kamni Vijay
    Kamni Vijay, CEO - Enable Medicine
    Andrei Georgescu
    Andrei Georgescu, CEO & Founder - Vivodyne
    Daniel Silva Manzano
    Daniel Silva Manzano, CEO & Co-Founder - Monod Bio
    Abe Heifets
    Abe Heifets, CEO & Co-Founder - Atomwise
  2. Blueprints for Biotech: Designing Deals that Deliver
    Breakout Session
    • Business Development and Finance
    32AB
    Matthew Hudes
    Matthew Hudes, Founder & CEO - BdlBiologx
    Christopher Walsh
    Christopher Walsh, Senior Vice President, General Counsel - Denali Therapeutics Inc.
    Bryan Glaser
    Bryan Glaser, Senior Vice President, Business Development - Invenra Inc.
    Saira Ramasastry
    Saira Ramasastry, Partner - LSA / Sanacor
    Grace Han McMahon
    Grace Han McMahon, Associate Vice President and Head of Merck’s BD&L Pacific Innovation Hub - Merck
  3. Case Studies: Bioprocessing of the Future
    BP
  4. Developing Successful DEI Programs for Life Sciences Companies
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Marredia Crawford
    Marredia Crawford, Chief Inclusion, Diversity and Equity Officer - Baker McKenzie
    Nicole Stovall
    Nicole Stovall, AVP, Diversity Strategy and Innovation - Merck
    Alessandra Ravetti
    Alessandra Ravetti, Senior Vice President, Associate General Counsel - Regeneron Pharmaceuticals
  5. Driving Biotech Success: What Every CEO Needs from Her C-Level Team
    Breakout Session
    • Business Development and Finance
    29AB
    Mary Haak-Frendscho
    Mary Haak-Frendscho, President and CEO - Spotlight Therapeutics
    Karen Boezi
    Karen Boezi, Chief Operating Officer - Thirona Biosciences
    Seema Kantak
    Seema Kantak, Senior Vice President, Biotherapeutics - Exelixis
    Nikita Jaipuria
    Nikita Jaipuria, Business Development, Senior Manager, Transactions - Amgen
    Cindy Dunkle
    Cindy Dunkle, Chief People Officer - Denali
  6. Navigating the Intersection of National Security and Advances in Emerging Biotechnology
    Breakout Session
    • Environmental Sustainability
    John Murphy
    John Murphy, Chief Policy Officer - Biotechnology Innovation Organization (BIO)
  7. Organizing to Derisk Academic Assets
    Breakout Session
    • Translational Research
    31AB
    Michelle Hoffmann
    Michelle Hoffmann, Executive Director - Chicago Biomedical Consortium
    Lisa Dhar
    Lisa Dhar, Associate Vice President for Innovation and New Ventures - Northwestern Innovation and New Ventures Office
    Aleks Baranczak
    Aleks Baranczak, Chief Program Officer - Blackbird Labs
    Craig Linsdley
    Craig Linsdley, University Professor of Pharmacology William K. Warren, Jr. Chair in Medicine - Vaderbilt University
    Eric Schiffhauer
    Eric Schiffhauer, Director of Outreach - Deerfield Management
    Jonathan Young
    Jonathan Young, Head of WARF Therapeutics - Wisconsin Alumni Research Foundation (WARF)
  8. PDABs and the IRA: The Impact of Federal Legislation on State-Level Prescription Pricing Practices
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Elizabeth (Liz) Helms
    Elizabeth (Liz) Helms, President and CEO - California Chronic Care Coalition
    John O’Brien
    John O’Brien, President and CEO - National Pharmaceutical Council
    Christopher (Brett) Johnson
    Christopher (Brett) Johnson, Director, State Government Affairs - Amgen
    Tiffany Westrich-Robertson
    Tiffany Westrich-Robertson, Chief Executive Officer and Co-Founder - AiArthritis
    Alice Valder Curran
    Alice Valder Curran, Partner - Hogan Lovells
  9. PFDDs and Beyond: Different Roads to Patient-Inspired Drug Development
    Breakout Session
    • Patient Advocacy
    25ABC
    travere
    Sika Dunyoh
    Sika Dunyoh
    Danae' Bartke
    Danae' Bartke, Person living with HCU, Executive Director - HCU Network America
    Reenie McCarthy
    Reenie McCarthy, CEO - Stealth BioTherapeutics
  10. The Promise of Personalized Treatment Becoming Reality: How INT Will Change Oncology
    Breakout Session
    • Oncology
    26A

    merck logo

    Cynthia Bens
    Cynthia Bens, Senior Vice President - Personalized Medicine Coalition
    Scot Ebbinghaus
    Scot Ebbinghaus, Vice President and Therapeutic Area Head - Merck Research Laboratories
    Alicia Walker Rowell
    Alicia Walker Rowell, Vice President - AIM at Melanoma
    Michelle Brown
    Michelle Brown, Vice President, Portfolio Lead - Moderna
    Niklas Blomberg
    Niklas Blomberg, Executive Director - Innovative Health Initiative
  11. Thriving in the Age of Digital Insecurity: New Reporting Obligations and Cyber Resilience for Life Sciences Companies
    Breakout Session
    • AI and Digital Health
    24BC
    Justine Phillips
    Justine Phillips, Partner - Baker McKenzie
    Todd Hemmen
    Todd Hemmen, Chief, Cyber Technical Analytics and Operations Section, Cyber Division - US Department of Justice, Federal Bureau of Investigation
    Nick Arico
    Nick Arico, Supervisory Special Agent - US Department of Justice, Federal Bureau of Investigation
    Lisel Newton
    Lisel Newton, Senior Director, Information Security, Risk & Compliance - Gossamer Bio
    Anne Blake-Dreher
    Anne Blake-Dreher, Vice President and Assistant General Counsel - Perrigo
  12. Vaccinating Against Mistrust and Misinformation During an Infodemic
    Breakout Session
    • Infectious Disease and Vaccines
    30DE
    Silvia Taylor
    Silvia Taylor, Executive Vice President, Chief Corporate Affairs & Advocacy Officer - Novavax, Inc.
    Reed Tuckson
    Reed Tuckson, Managing Director / Co-Founder - Tuckson Health Connections, LLC / Black Coaliition Against COVID-19
    Pedro Martinez
    Pedro Martinez, Director, Health - UnidosUS
    Sue Peschin
    Sue Peschin, President and CEO - Alliance for Aging Research
    Joe Smyser
    Joe Smyser, CEO - The Public Good Projects (PGP)
3:20 PM – 3:30 PM
(PST)
  1. BioProcess Insider Interviews: Enzene
    BP
3:30 PM – 3:40 PM
(PST)
  1. BioProcess Insider Interviews
    BP
3:40 PM – 4:10 PM
(PST)
  1. Biomanufacturing Supply and Demand: Industry Trends and Projected Impacts
    BP BioProcess Theater
    Dawn Ecker
    Dawn Ecker, Managing Director, BioProcess Technology Group (BPTG) - BDO
4:15 PM – 5:15 PM
(PST)
  1. Adult Vaccination: New Vaccines, New Opportunities to Protect Public Health
    Breakout Session
    • Infectious Disease and Vaccines
    32AB

    merck logo

    Jannie Oosthuizen
    Jannie Oosthuizen, President - Merck
  2. Co-opting Biological Processes to Drug Cancer and Other Diseases
    Breakout Session
    • Oncology
    26B
    Mariana Mihalusova
    Mariana Mihalusova, Investor - Venrock
    Larry Hamann
    Larry Hamann, Co-founder/CEO - Interdict Bio
    Aetna Wun Trombley
    Aetna Wun Trombley, CEO - Lycia
    Bernd Boidol
    Bernd Boidol, CEO - Proxygen
    Brian Fiske
    Brian Fiske, Co-founder/CSO - Mythic Therapeutics
  3. Enhancing Clinical Trial Diversity Through a Patient-Centric, Data Driven Approach
    Breakout Session
    • Diversity‚ Equity and Inclusion
    31C
    Elena Martinez
    Elena Martinez, Professor, Herbert Wertheim School of Public Health and Human Longevity Science; Associate Director of Population Sciences - UC San Diego Moores Cancer Center
    Trevan Locke
    Trevan Locke, Assistant Research Director - Duke-Margolis Institute for Health Policy
    Megan Fesinmeyer
    Megan Fesinmeyer, Observational Research Senior Manager - Amgen
    Carla Rodriguez-Watson
    Carla Rodriguez-Watson, Director of Research
    Darryl Sleep
    Darryl Sleep, Head, Global Public Health - Amgen
  4. Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    23BC
    Stephen Morales
    Stephen Morales, Senior Principal - Blue Fin Group, An IntegriChain Company
    Gerry Gleeson
    Gerry Gleeson, Head of US Market Access - Sanofi
    Bill Sarraille
    Bill Sarraille, Retired Senior Partner - Sidley Austin LLC
    Albert Thigpen
    Albert Thigpen, Operating Advisor - Nautic Partners
    Bill Roth
    Bill Roth, Founding Partner - Blue Fin Group
  5. IPOs Are Starting to Come Back: Are You Ready?
    Breakout Session
    • Business Development and Finance
    29AB
    Rich Ramko
    Rich Ramko, Partner, US Biotech Leader - EY (Ernst & Young)
    Steven Spector
    Steven Spector, Executive Vice President, Head of Business Development and General Counsel - Longboard Pharma
    Brad Wolff
    Brad Wolff, Senior Managing Director |Global Advisory | Strategic Advisory | Mergers and Acquisition - Evercore
    Arvind Kush
    Arvind Kush, CFO - RayzeBio
    Kristin VanderPas
    Kristin VanderPas, Partner - Cooley
  6. Moving from the Lab Bench to the Biotech C-Suite: Insights on Running a Founder-Led Biotech
    Breakout Session
    • Translational Research
    31AB
    Max Bayer
    Max Bayer, Staff Reporter - Fierce Biotech
    Kevin Parker
    Kevin Parker, CEO and Co-founder - Cartography Biosciences
    Jordi Mata-Fink
    Jordi Mata-Fink, CEO and Co-founder - Gate Bioscience
    Trevor Martin
    Trevor Martin, CEO and Co-founder - Mammoth Biosciences
    Kira Poskanzer
    Kira Poskanzer, Founder-in-Residence - Arcadia Science
    Heather Bowerman
    Heather Bowerman, CEO & Founder - DotLab
  7. Overcoming Systemic Data Bias via AI and Digital Health Tools: Perspectives from Providers, Pharma and Innovators
    Breakout Session
    • AI and Digital Health
    24BC
    Alexis Bortniker
    Alexis Bortniker, Partner - Cooley LLP
    Kal Patel
    Kal Patel, CEO - Brightsight
  8. Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Precision Oncology
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Daryl Pritchard
    Daryl Pritchard, Senior Vice President - Personalized Medicine Coalition
    Jonathan Katchmore
    Jonathan Katchmore, Vice President of Commercial Diagnostic Strategy - Eli Lilly
    Peter Hulick
    Peter Hulick, Medical Director, Center for Personalized Medicine - NorthShore / Endeavor Health
    Robert Dumanois
    Robert Dumanois, Director, Reimbursement Strategy - Thermo Fisher Scientific
    Wendy Levin
    Wendy Levin, Chief Medical Officer - Biofidelity
7:00 PM – 9:00 PM
(PST)
  1. Gas Lamp Block Party
    Session
6:30 AM – 4:30 PM
(PST)
  1. Registration
    Session
9:00 AM – 10:00 AM
(PST)
  1. Achieving the WHO Cervical Cancer Elimination Targets: The Value of Innovation in Achieving Pivotal Public Health Goals
    Breakout Session
    • Infectious Disease and Vaccines
    23BC

    merck logo

    Citseko Staples Miller
    Citseko Staples Miller, , Managing Director, Healthcare and Life Science - FTI Consulting
    Beth Battaglino
    Beth Battaglino, CEO - HealthyWomen
    Jenelle Krishnamoorthy
    Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck
  2. Exploring Deal-Making Options for Your Portfolio of Assets
    Breakout Session
    • Business Development and Finance
    29AB
    Nisha Nanda
    Nisha Nanda, Group Vice President, Business Development - Eli Lilly
    Adam Rosenthal
    Adam Rosenthal, CEO and Founder - Star Therapeutics
    Bassil Dahiyat
    Bassil Dahiyat, President and Chief Executive Officer - Xencor, Inc.
    James Mutamba
    James Mutamba, Chief Business Officer - Arrakis Therapeutics
    Caroline Stark Beer
    Caroline Stark Beer, Chief Business Officer - Jnana Therapeutics
  3. Immune System Biomarkers: Can Our Antibodies Predict How We Will React to Disease and Immunotherapy?
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Moira Gunn
    Moira Gunn, Radio Host - BiotechNation
    Martin Gouldstone
    Martin Gouldstone, Chief Executive Officer - Oncimmune
    G. Scott Chandler
    G. Scott Chandler, Global Head, Personalized Health Care (PHC) Safety - F. Hoffmann-La Roche
    Ashley Orillion
    Ashley Orillion, Principle Scientist, AAb PAS Biomarker Platform Development Lead - Janssen Immunology
    Justina Fert-Bober
    Justina Fert-Bober, Project Scientist - Cedars Sinai Medical Center
  4. New Approaches in Radiopharmaceuticals
    Breakout Session
    • Oncology
    31AB
    Karen Tkach Tuzman
    Karen Tkach Tuzman, Director of Biopharma Intelligence, Head of Discovery and Preclinical Research - BioCentury
    Dave Greenwald
    Dave Greenwald, CEO of Aviko Radiopharmaceuticals and vice president, business development - Deerfield Management
    Ken Song
    Ken Song, former CEO - RayzeBio
    Suji Jeong
    Suji Jeong, Founding Partner - The SJR Group
    Jeevan Virk
    Jeevan Virk, Therapeutic Area Strategy Head - Novartis
  5. Revolutionizing Clinical Trials: Patient Registries, Wearable Tech, and Video Capture
    Breakout Session
    • Clinical Trials Innovations
    26B
    Klaus Romero
    Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Allison Moore
    Allison Moore, Founder/CEO - Hereditary Neuropathy Foundation
    Tina Duong
    Tina Duong, Dir, Clinical Outcomes R & D Stanford University - Stanford University
    Jason Colquitt
    Jason Colquitt, CEO - Across Healthcare
    Michelle Campbell
    Michelle Campbell, Associate Director, Stakeholder Engagement & Clinical Outcomes, Office of Neuroscience - FDA
  6. Surviving Turbulence: Extending Runway and Creating Value in Healthcare and Biotech
    Breakout Session
    • Business Development and Finance
    32AB
    Gwendolyn Wu
    Gwendolyn Wu, Reporter - BioPharma Dive
    Cristina Ghenoiu
    Cristina Ghenoiu, Investor - Mubadala Capital
    Nate Chang
    Nate Chang, Operating Partner, Life Sciences - Playground Global
    Rakhshita Dhar
    Rakhshita Dhar, Senior Director of Venture Investments Health - Leaps by Bayer
    Andy Seid
    Andy Seid, Partner - Bioluminescence Ventures
  7. The US Supreme Court and the End of Scientific Deference?
    Breakout Session
    • Regulatory Innovation
    31C
    Stacy Amin
    Stacy Amin, Former FDA Chief Counsel - Morrison Foerster
    Rob MacRae
    Rob MacRae, General Counsel - GSK
    Karen Day
    Karen Day, Senior Corporate Counsel - Pfizer
    Sarah Isgur
    Sarah Isgur, ABC News Analyst and Host, Advisory Opinions Podcast - ABC News
    Jim Stansel
    Jim Stansel, General Counsel - PhRMA
    Julie Lovas
    Julie Lovas, Deputy General Counsel - Department of Health and Human Services
  8. What’s Nex-T: Innovator Roundtable on T Cell Therapies in Oncology
    Breakout Session
    • Oncology
    24BC
    Angus Liu
    Angus Liu, Senior Writer - Fierce Pharma / Fierce Biotech
    Keir Loiacono
    Keir Loiacono, Chief Executive Officer - BlueSphere Bio
    Dan Passeri
    Dan Passeri, Chief Executive Officer - Cue Biopharma
    David Fontana
    David Fontana, Chief Operating and Chief Business Officer - Umoja Biopharma
10:15 AM – 11:15 AM
(PST)
  1. Advancing the Global Regulatory Decision-Making with Public Private Partnerships
    Breakout Session
    • Regulatory Innovation
    31C
    Susan Winckler
    Susan Winckler, CEO - Reagan-Udall Foundation for the FDA
    Klaus Romero
    Klaus Romero, Chief Executive Officer, Chief Science Officer - Critical Path Institute
    Adora Ndu
    Adora Ndu, Chief Regulatory Affairs Officer - BridgeBio
    Carlos Garner
    Carlos Garner, Senior Vice President, Global Regulatory Affairs - Eli Lilly
  2. Approaching the Tipping Point: The Emergence of Allogeneic Cell Therapy for Oncology
    Breakout Session
    • Oncology
    31AB
    George Eastwood
    George Eastwood, Board Chair/Interim Executive Director - The Emily Whitehead Foundation
    Cokey Nguyen
    Cokey Nguyen, Chief Scientific and Technical Officer - Atara Biosciences
    Abigail Jenkins
    Abigail Jenkins, President & CEO - Gamida Cell
    P.K. Morrow
    P.K. Morrow, Senior Vice President and Head of Oncology Therapeutic Area Unit - Takeda
    Kristin Yarema
    Kristin Yarema, President & CEO - Poseida Therapeutics
  3. Changing the Game: Innovation to End HIV
    Breakout Session
    • Infectious Disease and Vaccines
    29C
    Cecilia Chung
    Cecilia Chung, Senior Director, Strategic Initiatives and Evaluation - Transgender Law Center
    Micheal Ighodaro
    Micheal Ighodaro, Co-Executive Director - Prevention Access Campaign
    Jenelle Krishnamoorthy
    Jenelle Krishnamoorthy, Vice President, Head of Global Public Policy and International Affairs - Merck
    Ji Ma
    Ji Ma, Head of Discovery - Brii Biosciences
    Sandra Thurman
    Sandra Thurman, Senior Advisor to the Division of Global HIV and Tuberculosis - CDC
  4. Competing as a Diagnostic Company in the Current Funding Environment: New Funding Models
    Breakout Session
    • Diagnostics and Personalized Medicine
    26A
    Bernard Peperstraete
    Bernard Peperstraete, CEO and Co-Founder - AcuamarkDx
    Magali Haas
    Magali Haas, CEO and President - Cohen Veterans Bioscience
  5. Inside the VC Playbook: Overcoming Obstacles in Challenging Markets for Success
    Breakout Session
    • Business Development and Finance
    32AB
    Kimberly Ha
    Kimberly Ha, Founder - KKH Advisors
    Troy Ignelzi
    Troy Ignelzi, Executive Advisor - Sofinnova Investments
    Andrew Lam
    Andrew Lam, Head of Biotech Investment - Ally Bridge Group
    Enoch Kariuki
    Enoch Kariuki, President - Endeavor Biomedicines
    Sheila Gujrathi
    Sheila Gujrathi, Biotech Executive and Entrepreneur
    Carol Gallagher
    Carol Gallagher, Independent Director
  6. Is Oncology Still a Hot Spot for Biopharma Deals?
    Breakout Session
    • Oncology
    24BC
    Ashwin Singhania
    Ashwin Singhania, Partner/Principal - EY (Ernst & Young)
    Ben Hickey
    Ben Hickey, President - RayzeBio
    Christopher Mortko
    Christopher Mortko, Vice President, Head of Search and Evaluation, Business Development & Licensing - Merck
    Ross Aarons
    Ross Aarons, Head of Oncology Business Development - Jazz Pharmaceuticals
  7. Partnering with ARPA-H: New Opportunities and Best Practices for Engaging a Transformative R&D Funder
    Breakout Session
    • Business Development and Finance
    29AB
    Susan Monarez
    Susan Monarez, Deputy Director - Advanced Research Projects Agency for Health (ARPA-H)
    Jason Roos
    Jason Roos, Director, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)
    Wade Shen
    Wade Shen, Director, Proactive Health - Advanced Research Projects Agency for Health (ARPA-H)
  8. Regulators & DTRA Enabling DCTs
    Breakout Session
    • Clinical Trials Innovations
    26B
    Amir Kalali
    Amir Kalali, Co Chair - DTRA
    Jane Myles
    Jane Myles, Program Director - DTRA
    Rasika Kalamegham
    Rasika Kalamegham, Head US Regulatory Policy - Genentech
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
3:00 PM – 4:00 PM
(PST)
  1. Closing Happy Hour
    Session

OTT banner ad
white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS

Loading

Search